山西特色产品走进外交部—太原市
为更好践行外事为企为民服务理念，统筹山西外事资源服务国家总体外交，帮助企业通过外交外事渠道“走出去”，省外事办和外交部服务局将于端午节前在外交部举办“魅力山西晋在眼前——山西特色产品走进外交部”活动。
In order to further practice the concept of foreign affairs serving both enterprises and the public, coordinate Shanxi's foreign affairs resources to serve the overall national diplomacy, and assist enterprises’ going-global strategy through diplomatic channels, the Service Center for the Foreign Ministry and Its Overseas Missions, along with the Foreign Affairs Office of the People's Government of Shanxi Province, jointly organized the "Charming Shanxi·Choosing Shanxi — Shanxi Specialties Entering the Ministry of Foreign Affairs" event at the Ministry of Foreign Affairs.
经多轮甄选企业和产品，按照企业知名、产品优质、自愿参与的原则，共甄选出共有68家企业600余款产品参加活动，涉及山西重点产业链、“专精特新”小巨人企业、农业产业化龙头企业、特色专业镇、上市企业、中华老字号、山西精品及非遗等。山西也是首家全省域范围在外交部举办此类活动的省（区、市）。
After multiple rounds of selection for enterprises and products, based on the principles of enterprise reputation, product quality, and voluntary participation, a total of 68 enterprises with approximately 700 products were selected to participate. These products cover key Shanxi industry chains, industry-specific towns, listed companies, time-honored Chinese brands, Shanxi quality products, and intangible cultural heritage items. Shanxi is also the first province to hold a province-wide promotional event at the Ministry of Foreign Affairs.
一、山西锦波生物医药股份有限公司 Shanxi Jinbo Biomedical Technology Co., Ltd.
国家级“专精特新”小巨人企业，山西省重点产业链合成生物产业链“链主”企业，是中国原始创新重组人源化胶原蛋白医用新材料医疗器械行业标准制定者，拥有发明专利授权50项，其中国际发明专利授权3项。公司立足人体结构性材料和人类重大传染病两大领域，完成了多项原始创新成果0-1的突破。运用结构生物学和合成生物学国际前沿技术，成为国际首个实现具有高级三螺旋结构“A型人源化胶原蛋白”规模化绿色智造的企业。在人类重大传染病领域，运用病毒进入抑制新理论，首次实现了广谱抗HPV生物蛋白、广谱抗新冠病毒多肽药物的产业化及终端产品开发。
As a national-level "specialized, refined, special, and new" (SRSN) small and medium-sized enterprise, Shanxi Jinbo Biomedical Technology Co., Ltd. is the "chain leader" of Shanxi's synthetic biotechnology industry chain. It is the standard setter for the medical device industry of original innovative recombinant human collagen medical materials, and has been granted 50 invention patents, including 3 international invention patents. Focusing on human structural materials and major human infectious diseases, the company has achieved breakthroughs in a number of original innovative achievements. By employing cutting-edge technologies in structural biology and synthetic biology, it has become the world's first enterprise to achieve large-scale green manufacturing of advanced triple helix structure "Type A Recombinant Human Collagen". In the field of major human infectious diseases, by employing the theory of virus entry inhibition, it has achieved the industrialization and terminal product development of broad-spectrum anti-HPV bioproducts and broad-spectrum anti-coronavirus peptide drugs for the first time.